Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging - PubMed
2 hours ago
- #Lecanemab
- #Alzheimer's Disease
- #MRI Imaging
- Lecanemab treatment in early Alzheimer's disease patients was linked to reduced gray matter volume in vulnerable brain regions like the hippocampus, entorhinal cortex, and precuneus.
- The study observed increased cerebrospinal fluid (CSF) volumes, including ventricular expansion, alongside a modest, non-significant decline in perivascular space (PVS) volume.
- Choroid plexus (CP) enlargement was associated with ventricular expansion, suggesting CP and PVS dynamics could serve as MRI-based markers for monitoring early Alzheimer's disease progression and treatment effects.